Navigation Links
Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors
Date:2/6/2012

ROCKVILLE, Md., Feb. 6, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that Wei-Wu He, Ph.D has joined the Board of Directors as Executive Chairman and Tak W. Mak, Ph.D has joined as a member of the Board of Directors.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )

Dr. Wei-Wu He is currently the CEO and Chairman of OriGene Technologies, Inc. He also is the founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established in Maryland since 2000. Dr. He was also one of the first few employees at Human Genome Sciences, Inc. and from 1993 to 1996 was a scientist at the company.  Prior to that he was a Research Fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He has been involved in founding and funding over 20 biotech companies throughout his career.  Dr. He received his Ph.D. from Baylor College of Medicine and MBA from The Wharton School of University of Pennsylvania.  Dr. He is an author to more than 25 research publications and inventor of over 30 issued patents.  

Dr. Tak W. Mak is currently the Director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Hospital and a University Professor in the Department of Medical Biophysics and Department of Immunology, University of Toronto.  He was trained at the University of Wisconsin in Madison, the University of Alberta and the Ontario Cancer Institute.  He is best known as the leading scientist of the group that first cloned the genes of the human T cell antigen receptor.  Dr. Mak is an Officer of the Order of Canada, and has been elected a Foreign Associate of the National Academy of Sciences (USA), a Foreign Associate of the American Academy of Arts and Sciences, as well as a Fellow of the Royal Society of London (UK). He was recently awarded the Order of Ontario and has won international recognition in the form of the Emil von Behring Prize, the King Faisal Prize for Medicine, the Gairdner Foundation International Award, the Sloan Prize of the General Motors Cancer Foundation, the Novartis Prize in Immunology and the Paul Ehrlich Prize and Ludwig Darmstaedter Prize of Germany. Dr. Mak's held the position of VP of Research at Amgen, Inc. and was Director of the Amgen Institute in Toronto from 1993-2002. His experience as a venture capitalist allows him to be an integral part of start-up companies.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma.  ENMD-2076 is currently in a Phase 2 trial for ovarian cancer, and preclinical and clinical activities are ongoing in assessing the compound's applicability for other forms of cancer.

Forward Looking Statements         

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; our reliance on a single product candidate, ENMD-2076 and the risk that we may not be able to license it to a third party; the volatility of our common stock; our history of losses and expectation of incurring continued losses; risks relating to the need for additional capital, including the uncertainty of securing additional funding on favorable terms; the need for additional funds to conduct any additional clinical trials, our dependence on royalty sharing agreement based on sales of a product, Thalomid®, that we do not control; declines in actual sales of Thalomid® resulting in materially reduced royalty payments; risks associated with our product candidates; results in preclinical models that are not necessarily indicative of clinical results;  risks relating to the commercialization, if any, of our  proposed products (such as marketing, safety, regulatory, patent, product liability, supply and other risks); and our ability to compete with larger, better financed biotechnology companies that may develop new approaches to the treatment of our targeted diseases or develop product candidates more advanced than ENMD-2076.  Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition.  We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the SEC, which are available at www.sec.gov.

COMPANY CONTACT:
Investor Relations
EntreMed, Inc.
240.864.2643
investorrelations@entremed.com


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. European Pharmaceutical and Biotech Contract Manufacturing Markets
2. Biotechnology Pharmaceutical Company Selects NewCardios QTinno for Thorough QT Trial
3. Leaders of Healthcare, Biotech and Pharmaceutical Companies Sending Proclamation to President Obama and Congress Urging Solution to Nations Healthcare Crisis
4. Aethlon Medical Discloses Availability of the Biotech Showcase™ 2012 Presentation
5. Lixte Biotechnology Holdings Announces Issuance of U.S. Patent for Agents for the Treatment of Neurodegenerative Diseases
6. GenturaDx to Present at the Biotech Showcase Conference
7. Inovio Pharmaceuticals to Present at Biotech Showcase Investor Conference
8. Trinity Biotech to Present at Sidoti & Companys Semiannual New York Micro-Cap Conference on January 9, 2012
9. Aethlon Medical Announces Biotech Showcase™ 2012 Presentation
10. Ikaria® to Present at Biotech Showcase™ 2012
11. Express Scripts HealthBridge Pharma & Biotech to Provide Specialty Pharmacy and Specialty Distribution Services for EYLEA™ (aflibercept) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... New York , February 10, 2016 ... Growth, Trends and Forecast 2015 - 2023 ", reveals that ... rather slow growth from 2015 to 2023 owing to patent ... a meager CAGR of 1.30% during the forecast period, the ... to US$38.9 bn in 2023. --> Antibacterial Drugs ...
(Date:2/10/2016)... 10, 2016 Intouch Solutions, a leading marketing ... industry-wide trend regarding the evolution of digital sales ... efficiently deliver compelling sales presentations via tablets. After ... in 2015, Intouch uncovered that while most pharmaceutical ... DSAs, many are not using them effectively during ...
(Date:2/10/2016)... , Feb. 9, 2016 ... Drug Administration (FDA) met with its Arthritis ... proposed biosimilar of Johnson & Johnson,s Remicade ... be approved in the U.S. The Biologics ... physician groups - Alliance for Patient Access, ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... ... full-service health care communications company offering education, research and medical media, has ... and specialists working in infectious diseases. , As the all-inclusive resource for ...
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing series ... 2016. Each webinar features a dynamic expert and thoughtful presentation to give attendees ... and facilities. Both events are free to attend, but registration is required. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... The Guard, to associations of medical professionals throughout the country. The Guard was ... risk assessments, policies and procedures, employee training, regulatory updates, and compliance coaching. , ...
(Date:2/10/2016)... ... 2016 , ... 10 Best Water is excited to announce a ... owners that topped the list as a result of their commitment to offering clients ... was Tibet 5100, a top notch water company that specializes in providing the public ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Ongoing news of ... Life Care Association™ (ALCA) to conduct a survey that takes a closer look at ... today illustrates the prevalence and causes of TBI among the aging population, and identifies ...
Breaking Medicine News(10 mins):